| Seventy percent of AD clinical trials are assessing non-Aβ, non-tau targets with novel agents. |
| Inflammation and synaptic plasticity/neuroprotection are the CADRO categories with the largest number of novel candidate therapies. |
| Evaluation of non-canonical targets are novel therapeutic strategies for the disease-modifying treatment of AD. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.